Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
The Thermo Fisher Scientific Baltics Uab portfolio is active in the Biotechnology & Pharmaceuticals technology area. Prosecution activity is currently limited to 1 distinct examiner and 1 distinct art unit. This indicates a specialized focus for the current patent applications.
EDWARDS, JESSICA FAYE is identified as the busiest examiner for this portfolio. This examiner is currently handling 1 busiest examiner pending office action. This action represents the total 1 pending office actions for the portfolio.
With 1 distinct examiner and 1 distinct art unit, the prosecution process is centralized. The 1 pending office action is the outstanding matter that practitioners need to address. Success in the Biotechnology & Pharmaceuticals field for this entity hinges on the resolution of this action with EDWARDS, JESSICA FAYE. The fact that the portfolio is managed by an individual examiner suggests that the prosecution will receive a focused review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDWARDS, JESSICA FAYE | 1 | 39.1% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775253 | DEOXYRIBONUCLEASE VARIANTS AND USES THEREOF | EDWARDS, JESSICA FAYE | 5d |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17775253 | DEOXYRIBONUCLEASE VARIANTS AND USES THEREOF | EDWARDS, JESSICA FAYE | 1657 | §112 | Final Rejection | 5d | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial